Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02387762 · ClinicalTrials.gov registry record · Phase 2
ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate
A Phase 2 study of Rheumatoid Arthritis, sponsored by Acerta Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 17
- Study locations
NCT02387762: Completed Phase 2 study of Rheumatoid Arthritis, sponsored by Acerta Pharma.
NCT02387762 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Acerta Pharma. The registered enrollment target is 31 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02387762, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Acerta Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 17
- Study locations
Study Summary
This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of ACP-196 in subjects with Rheumatoid Arthritis on background Methotrexate.
Primary Outcome
Disease activity score 28 - C-reactive protein (DAS28-CRP) is a score to measure disease activity in patients with rheumatoid arthritis by aggregating data of 28 joints, and is calculated by the scores on scale using the following variables: The number of swollen and tender joints, CRP level, and patient's global assessment of disease activity. The total score of the DAS28 values may range from 2.0 to 10.0 while higher values mean a higher disease activity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG acalabrutinib
Study Locations (17)
California
- TriWest Research Associates, LLC - El Cajon
- Neuropsychiatric Research Center of Orange County - Orange
- Pacific Arthritis Center Medical Group - Santa Monica
- Inland Rheumatology and Osteoporosis Medical Group, Inc - Upland
Florida
- San Marcus Research Clinic, Inc. - Hialeah
- Suncoast Clinical Research, Inc. - New Port Richey
- Suncoast Clinical Research - New Port Richey
- The Arthritis Center - Palm Harbor
Alabama
- Pinnacle Research Group - Anniston
- Achieve Clinical Research - Birmingham
Arizona
- Advanced Arthritis Care and Research - Scottsdale
Nevada
- Office of George Timothy Kelly, MD - Las Vegas
North Carolina
- PMG Research of Salisbury - Salisbury
Oklahoma
- Health Research of Oklahoma - Oklahoma City
Pennsylvania
- Altoona Center for Clinical Research - Duncansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
What the finished NCT02387762 record still lists
NCT02387762 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02387762 lists 17 locations in 10 states (California, Florida, Alabama).
Frequently Asked Questions
What is clinical trial NCT02387762 about?
NCT02387762 is a clinical study titled "ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate". This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of ACP-196 in subjects with Rheumatoid Arthritis on background Methotrexate.
What is the current status of trial NCT02387762?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2015-04. Estimated completion is 2016-06.
What conditions does trial NCT02387762 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT02387762?
The interventions under investigation include: Placebo (DRUG), acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT02387762?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02387762 being conducted?
This trial has 17 study locations across Alabama, Arizona, California, Florida, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02387762's enrollment target sits among peer trials
31 159th of 197 higher than 37 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia